Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Pharnext

    MCap

    1m

    Last close

    EUR0.10

    ▲ 0.03 (42.86%)

    MoneyHero

    MCap

    USD60m

    Last close

    USD2.35

    ▲ 0.55 (30.56%)

    MGI – Media and Games Invest

    MCap

    EUR235m

    Last close

    EUR1.50

    ▲ 0.35 (30.21%)

  • Sectors

    Sectors

  • Investment Strategy

    Investment Strategy

    View All

    Latest

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Sequana Medical – executive interview

Sequana Medical – executive interview

Sequana Medical — 3 videos in collection

More on this equity

Based in Belgium, Sequana Medical develops and commercialises products to treat diuretic-resistant fluid overload, a frequent complication of liver disease and heart failure. Its proprietary alfapump and DSR approaches aim to provide significant clinical and quality-of-life benefits in these fluid overload conditions.

In this interview, CEO Ian Crosbie describes how the alfapump may provide material benefits for patients with recurrent and refractory ascites as shown in pivotal data from its POSEIDON North American registration study, with US market approval projected before the end of 2024. Crosbie highlights the promising results shown so far for its DSR 2.0 product in patients with persistent congestion due to heart failure, including from the recent non-randomised cohort of its US MOJAVE Phase I/IIa study, and he discusses the next steps ahead for this programme.

< Previous
Next >

You may also be interested in these:

Healthcare

Sequana Medical – Executive Interview

Healthcare

Sequana Medical – executive interview

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free